# The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

> **NCT01836523** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1398 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo
- **DRUG:** liraglutide
- **DRUG:** placebo
- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01836523
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 1398 (ACTUAL)
- **Last updated:** 2017-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836523, "The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01836523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*